全文获取类型
收费全文 | 73123篇 |
免费 | 5451篇 |
国内免费 | 368篇 |
专业分类
耳鼻咽喉 | 746篇 |
儿科学 | 1919篇 |
妇产科学 | 1817篇 |
基础医学 | 9333篇 |
口腔科学 | 1740篇 |
临床医学 | 7342篇 |
内科学 | 16351篇 |
皮肤病学 | 937篇 |
神经病学 | 5851篇 |
特种医学 | 2131篇 |
外国民族医学 | 2篇 |
外科学 | 10895篇 |
综合类 | 1284篇 |
现状与发展 | 1篇 |
一般理论 | 112篇 |
预防医学 | 6322篇 |
眼科学 | 2037篇 |
药学 | 5337篇 |
中国医学 | 167篇 |
肿瘤学 | 4618篇 |
出版年
2023年 | 304篇 |
2022年 | 470篇 |
2021年 | 1353篇 |
2020年 | 831篇 |
2019年 | 1151篇 |
2018年 | 1412篇 |
2017年 | 973篇 |
2016年 | 1138篇 |
2015年 | 1314篇 |
2014年 | 1976篇 |
2013年 | 3236篇 |
2012年 | 4360篇 |
2011年 | 4738篇 |
2010年 | 2682篇 |
2009年 | 2503篇 |
2008年 | 4535篇 |
2007年 | 4751篇 |
2006年 | 4563篇 |
2005年 | 4639篇 |
2004年 | 4343篇 |
2003年 | 3931篇 |
2002年 | 3920篇 |
2001年 | 987篇 |
2000年 | 825篇 |
1999年 | 928篇 |
1998年 | 841篇 |
1997年 | 723篇 |
1996年 | 603篇 |
1995年 | 582篇 |
1994年 | 539篇 |
1993年 | 507篇 |
1992年 | 691篇 |
1991年 | 648篇 |
1990年 | 539篇 |
1989年 | 547篇 |
1988年 | 520篇 |
1987年 | 497篇 |
1986年 | 466篇 |
1985年 | 519篇 |
1984年 | 527篇 |
1983年 | 485篇 |
1982年 | 603篇 |
1981年 | 528篇 |
1980年 | 556篇 |
1979年 | 376篇 |
1978年 | 380篇 |
1977年 | 373篇 |
1976年 | 322篇 |
1975年 | 334篇 |
1974年 | 308篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
Rajendrababu Sharmila Puthuran George Varghese Alia Laxmi Ananya Uduman Mohammed Sithiq Wijesinghe Hiruni Kaushalya 《International ophthalmology》2022,42(8):2609-2618
International Ophthalmology - To investigate the efficacy and safety of non-valved Aurolab aqueous drainage implant (AADI) surgery combined with phacoemulsification in eyes with refractory glaucoma... 相似文献
3.
4.
5.
6.
7.
8.
9.
Toidi Adekambi Chris C. Ibegbu Stephanie Cagle Ameeta S. Kalokhe Yun F. Wang Yijuan Hu Cheryl L. Day Susan M. Ray Jyothi Rengarajan 《The Journal of clinical investigation》2015,125(5):1827-1838
BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient’s sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.METHODS. Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.RESULTS. Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.CONCLUSION. We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure.TRIAL REGISTRATION. Registration is not required for observational studies.FUNDING. This study was funded by Emory University, the NIH, and the Yerkes National Primate Center. 相似文献